Enanta Pharmaceuticals Inc (ENTA)

[willyw]

It appears to me that ENTA is looking at developing their own self funded HCV program.

So far, I think they have a number of potentials, but there is nothing in the program at the moment.

Novartis is finishing up the NS5A phase 2A trial results and will hand them over to ENTA.... call it year end
This would be the most advanced unattached asset that Enta has in trials. Luly spend more time talking about the NS5A than other unattached ENTA assets.

Per the last stock CC CS healthcare in mid November;
file:///C:/Documents%20and%20Settings/Administrator/My%20Documents/Downloads/Enanta%20v2%20Final%20Nov12%281%29.pdf
(page 17)
"Currently evaluating development plan forward for EDP-239 combinations"
==============
per the same pitch, on page 18

"Proprietary High Resistance Barrier
Preclinical Programs
•
Cyclophilin Inhibitors and Nuc Polymerase Inhibitors
•
Discovery / preclinical activities ongoing
•
Next step: candidate selection for one or both
•
High resistance barrier mechanisms and scarcity of
inhibitors make both classes attractive"
===========================================

So maybe the NS5A is a given, and ENTA may select one or both of the others to develop. I just can't tell from what I heard/read.

But they have a good track record, do they not?